


Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application.

## Claims 1-187 (cancelled)

## Claim 188 (new) A compound of the formula



or a pharmaceutically acceptable salt thereof wherein  
 A1  
 R<sub>1</sub> is:

- (I) C<sub>1</sub>-C<sub>6</sub> alkyl, unsubstituted or substituted with one, two or three C<sub>1</sub>-C<sub>3</sub> alkyl, -F, -Cl, -Br, -I, -OH, -NH<sub>2</sub>, -C≡N, -CF<sub>3</sub>, or -N<sub>3</sub>,
- (II) -(CH<sub>2</sub>)<sub>1-2</sub>-S-CH<sub>3</sub>,
- (III) -CH<sub>2</sub>-CH<sub>2</sub>-S-CH<sub>3</sub>,
- (IV) -CH<sub>2</sub>-(C<sub>2</sub>-C<sub>6</sub> alkenyl) unsubstituted or substituted by one -F,
- (V) -(CH<sub>2</sub>)<sub>0-3</sub>-(R<sub>1</sub>-aryl) where R<sub>1</sub>-aryl is phenyl, 1-naphthyl, 2-naphthyl, indanyl, indenyl, dihydronaphthyl, tetralinyl unsubstituted or independently substituted on the aryl ring with one or two of C<sub>1</sub>-C<sub>3</sub> alkyl, -CF<sub>3</sub>, -F, Cl, -Br, -I, C<sub>1</sub>-C<sub>3</sub> alkoxy, -O-CF<sub>3</sub>, -NH<sub>2</sub>, -OH, or -C≡N;

R<sub>2</sub> is:

- (I) -H,
- (II) C<sub>1</sub>-C<sub>6</sub> alkyl, or

(III)  $-(CH_2)_{0-4}-R_{2-1}$  where  $R_{2-1}$  is  $(C_3-C_6)$  cycloalkyl,  $R_{1-aryl}$  where  $R_{1-aryl}$  is optionally substituted with  $R_{100}$ , where  $R_{100}$  is

- (1)  $C_1-C_6$  alkyl,
- (2)  $-F$ ,  $-Cl$ ,  $-Br$ , or  $-I$ ,
- (3)  $-OH$ ,
- (4)  $-NO_2$ ,
- (5)  $-CO-OH$ ,
- (6)  $-C\equiv N$ ,
- (7)  $-CO-NR_{N-2}R_{N-3}$  where  $R_{N-2}$  and  $R_{N-3}$  are the same or different and are:
  - (a)  $-H$ ,
  - (b)  $-C_1-C_6$  alkyl unsubstituted or substituted with one  $-OH$  or  $-NH_2$ ,
  - (c)  $-C_1-C_6$  alkyl unsubstituted or substituted with one to three  $-F$ ,  $-Cl$ ,  $-Br$ , or  $-I$ ,
  - (d)  $-C_3-C_7$  cycloalkyl,
  - (e)  $-(C_1-C_2$  alkyl)  $-(C_3-C_7$  cycloalkyl),
  - (f)  $-(C_1-C_6$  alkyl)  $-O-(C_1-C_3$  alkyl),
  - (g)  $-C_1-C_6$  alkanyl with one or two double bonds,
  - (h)  $-C_1-C_6$  alkynyl with one or two triple bonds,
  - (i)  $-C_1-C_6$  alkyl chain with one double bond and one triple bond,
- (8)  $-CO-(C_3-C_{12}$  alkyl),
- (9)  $-CO-(C_3-C_6$  cycloalkyl),
- (11)  $-CO-R_{1-heterocycle}$  where  $R_{1-heterocycle}$  is morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide, piperazinyl, homopiperazinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyrananyl, piperidinyl, tetrahydrofurananyl, or tetrahydrothiophenyl.

where the  $R_1$ -heterocycle group is bonded by any atom of the parent  $R_1$ -heterocycle group substituted by hydrogen such that the new bond to the  $R_1$ -heteroaryl group replaces the hydrogen atom and its bond, where heterocycle is unsubstituted or substituted with one or two

=O,  $C_1$ - $C_3$  alkyl, - $CF_3$ , -F, Cl, -Br, -I,  $C_1$ - $C_3$  alkoxy, - $OCF_3$ , - $NH_2$ , -OH, or - $C\equiv N$ ,

(12) -CO- $R_{N-4}$  where  $R_{N-4}$  is morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl or pyrrolidinyl where each group is unsubstituted or substituted with one or two  $C_1$ - $C_3$  alkyl,

(13) -CO-O- $R_{N-5}$  where  $R_{N-5}$  is:

- (a)  $C_1$ - $C_6$  alkyl, or
- (b) - $(CH_2)_{0-2-}$ - $(R_1$ -aryl) where  $R_1$ -aryl is as defined above,

(14) - $SO_2$ - $NR_{N-2}R_{N-3}$  where  $R_{N-2}$  and  $R_{N-3}$  are as defined above,

(15) - $SO$ - $(C_1$ - $C_6$  alkyl),

(16) - $SO_2$ - $(C_3$ - $C_{12}$  alkyl),

(17) - $NH$ -CO-O- $R_{N-5}$  where  $R_{N-5}$  is as defined above,

(18) - $NH$ -CO-N( $C_1$ - $C_3$  alkyl)<sub>2</sub>,

(19) - $N$ -CS-N( $C_1$ - $C_3$  alkyl)<sub>2</sub>,

(20) - $N$ ( $C_1$ - $C_3$  alkyl)-CO- $R_{N-5}$  where  $R_{N-5}$  is as defined above,

(21) - $NR_{N-2}R_{N-3}$  where  $R_{N-2}$  and  $R_{N-3}$  can be the same or different and are as defined above,

(22) - $R_{N-4}$  where  $R_{N-4}$  is as defined above,

(23) -O-CO- $(C_1$ - $C_6$  alkyl),

(24) -O-CO-N( $C_1$ - $C_3$  alkyl)<sub>2</sub>,

(25) -O-CS-N( $C_1$ - $C_3$  alkyl)<sub>2</sub>,

- (26) -O-(C<sub>1</sub>-C<sub>6</sub> alkyl),
- (27) -O-(C<sub>2</sub>-C<sub>5</sub> alkyl)-COCH<sub>3</sub>,
- (28) -S-(C<sub>1</sub>-C<sub>6</sub> alkyl),
- (29) C<sub>1</sub>-C<sub>6</sub> alkyl unsubstituted or substituted with 1, 2, 3, 4, or 5 -F,
- (30) -O-(C<sub>1</sub>-C<sub>6</sub> alkyl unsubstituted or substituted with 1, 2, 3, 4, or 5 -F, or
- (31) -O- $\phi$ ;

R<sub>N-1</sub> is phenyl that is independently substituted with one, two, three or four of R<sub>100</sub>;

R<sub>a</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sub>c</sub> is

A  
R<sub>CW</sub> where R<sub>CW</sub> is morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide, piperazinyl, homopiperazinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, tetrahydrofuranyl, or tetrahydrothiophenyl, each of which is optionally substituted with oxo, C<sub>1</sub>-C<sub>3</sub> alkyl, -CF<sub>3</sub>, -F, Cl, -Br or -I, C<sub>1</sub>-C<sub>3</sub> alkoxy, -O-CF<sub>3</sub>, -NH<sub>2</sub>, -OH, or -C≡N;

#1 B  
ZT  
10/6/04  
R<sub>CY</sub> where R<sub>CY</sub> is pyridinyl, pyrimidinyl, quinolinyl, indenyl, indanyl, benzothiophenyl, indolyl, indolinyl, pyridazinyl, pyrazinyl, isoindolyl, isoquinolyl, quinazolinyl, quinoxalinyl, ~~hthalazinyl~~, ~~imidazoly~~, isoxazolyl, pyrazolyl, oxazolyl, thiazolyl, indolizinyl, indazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, furanyl, thieryl, pyrrolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, 1, 4-benzodioxanyl, purinyl, oxazolopyridinyl, imidazopyridinyl, isothiazolyl, naphthyridinyl, cinnolinyl, carbazolyl,  $\beta$ -carbolinyl,

isochromanyl, chromanyl, furazanyl,  
tetrahydroisoquinoline, isoindolinyl,  
isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl,  
isobenzothiophenyl, benzoxazolyl, or pyridopyridinyl,  
each of which is optionally substituted with C<sub>1</sub>-C<sub>3</sub> alkyl,  
-CF<sub>3</sub>, -F, Cl, -Br, or I, C<sub>1</sub>-C<sub>3</sub> alkoxy, -O-CF<sub>3</sub>, -NH<sub>2</sub>, -OH,  
or -C≡N;  
- (C<sub>1</sub>-C<sub>10</sub>) alkyl-R<sub>CH</sub>; or  
- (C<sub>1</sub>-C<sub>10</sub>) alkyl-R<sub>CY</sub>.

Claim 189 (new) A compound according to claim 172, which  
is N-[1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-  
(piperidine-1-carbonyl)-hexyl]-N,N-dipropyl-isophthalamide.

Claim 190 (new) A compound according to claim 172, which  
is N-[1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-(2-  
morpholin-4-yl-ethylcarbamoyl)-pentyl]-5-methyl-N,N-dipropyl-  
isophthalamide.

Claim 191 (new) A compound according to claim 172, which  
is N-[1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-  
[(tetrahydro-furan-2-ylmethyl)-carbamoyl]-pentyl]-5-methyl-N,N-  
dipropyl-isophthalamide.

Claim 192 (new) A compound according to claim 172, which  
is N-[1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-methyl-5-  
morpholin-4-yl-5-oxo-pentyl]-5-methyl-N,N-dipropyl-  
isophthalamide.

Claim 193 (new) A compound according to claim 172, which  
is N-[1-(S)-(3,5-Difluoro-benzyl)-4-(R)-[(furan-2-ylmethyl)-

carbamoyl]-2-(S)-hydroxy-pentyl)-5-methyl-N,N-dipropyl-isophthalamide.

194. (new) A pharmaceutical composition comprising a compound according to claim 188 in combination with a pharmaceutically acceptable carrier.

*A1*  
*#11B2*  
*21*  
*10/6/04*

195. (new) A method according of treating or preventing Alzheimer's Disease comprising administering to a subject in need of such treatment an effective amount of a compound according to claim 188.